A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

BACKGROUND: Dinaciclib, a small-molecule, cyclin-dependent kinase inhibitor, inhibits cell cycle progression and proliferation in various tumor cell lines in vitro. We conducted an open-label, dose-escalation study to determine the safety, tolerability, and bioactivity of dinaciclib in adults with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Nemunaitis, John J, Small, Karen A, Kirschmeier, Paul, Zhang, Da, Zhu, Yali, Jou, Ying-Ming, Statkevich, Paul, Yao, Siu-Long, Bannerji, Rajat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853718/
https://www.ncbi.nlm.nih.gov/pubmed/24131779
http://dx.doi.org/10.1186/1479-5876-11-259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853718/
https://www.ncbi.nlm.nih.gov/pubmed/24131779
http://dx.doi.org/10.1186/1479-5876-11-259

Ejemplares similares